Pay in 4 interest-free payments of $5.36 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
This research offers further insight into this emerging safety signal, according to the study authors who noted in their Ophthalmology paper, Our novel, stratified analysis provides a more nuanced interpretation than previous pooled reviews, isolating a potential increased risk signal to observational data in the diabetes population only, a finding not corroborated by RCTs. These results are somewhat at odds with the narrative surrounding GLP-1 use and NAION risk that began in early 2024, but the researchers say they are confident in their methodology
Whether cagrilintide dosage with retatrutide specifically emerges as a validated approach remains to be seen
Calories vary because GLP-1 users differ widely in body size, dose, activity, and weight-loss phase
A doctors consultation is essential to ensure the highest level of safety
